ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
애드세트리스 시장 규모는 최근 몇 년간 크게 성장했습니다. 2025년 140만 달러에서 2026년에는 152만 달러에 이르고, CAGR 8.9%의 성장이 전망되고 있습니다. 지난 수년간의 성장은 단일클론항체 연구의 발전, 호지킨림프종 발생률 증가, 재발암의 미충족 수요, 표적치료제의 임상적 성공, 항체-약물 복합체(ADC) 약물의 규제 승인 등에 기인하는 것으로 보입니다.
애드세트리스 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 212만 달러에 이르고, CAGR은 8.6%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 적응증 확대, 종양 생물학적 제제에 대한 투자 증가, 맞춤의료 도입 확대, 암 의료비 증가, ADC 제조의 확장성 향상 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 종양학 분야에서 항체-약물 복합제 사용 확대, 표적 암 치료 선호도 증가, 병용요법 채택 증가, 희귀 림프종 치료에 대한 관심 증가, CD30 양성 암의 임상 결과 개선 등을 들 수 있습니다.
암 발병률 증가는 향후 몇 년 동안 아세트트리스 시장의 성장을 견인할 것으로 예측됩니다. 암은 체내에서 비정상적인 세포가 통제할 수 없을 정도로 증식하고 확산되는 일련의 질병군을 말합니다. 암 발생률 증가는 건강에 해로운 생활습관(영양 부족, 운동 부족 등), 환경오염 물질에 대한 노출 증가, 조기에 발견할 수 있는 진단기술의 발전 등의 요인에 기인합니다. 애드세트리스는 CD30 양성 암세포를 선택적으로 표적화하여 강력한 세포독성 약물을 종양에 직접 전달함으로써 암 환자들에게 치료 효과를 높이고 전신 부작용을 감소시키는 놀라운 이점을 제공합니다. 이 표적치료제는 특정 호지킨림프종 및 CD30을 발현하는 다른 악성 종양 환자들에게 중요한 치료 옵션이 될 수 있습니다. 예를 들어, 미국 비영리 암 지원 단체인 미국암협회(American Cancer Society)에 따르면, 2023년 1월 기준 2023년 미국 내 신규 암 발생 건수는 약 195만 8,310건, 암 관련 사망자 수는 60만 9,820명으로 보고되고 있습니다. 따라서 암 부담 증가가 애드세트리스 시장 확대에 기여하고 있다고 볼 수 있습니다.
애드세트리스 시장을 형성하는 주요 동향으로는 치료 효과 향상, 부작용 억제, 암세포에 대한 보다 정밀한 표적화를 위해 개량형 항체 약물 복합체(ADC) 개발 및 병용요법을 포함한 약물 전달 방법의 고도화가 강조되고 있습니다. 병용요법이란 작용기전이 다른 두 가지 이상의 약물을 병용하는 치료법으로, 단독요법 대비 시너지 효과로 치료성적 개선, 약제 내성 감소, 독성의 잠재적 감소를 기대할 수 있습니다. 예를 들어, 2023년 10월 일본 제약사 다케다약품공업은 치료 경험이 없는 CD30 양성 3기 호지킨림프종 성인 환자를 위한 치료제로 애드세트리스(브렌툭시맙베도틴)와 독소루비신, 빈블라스틴, 다카르바진(AVD)의 병용요법을 유럽에서 승인받았습니다.에 대해 유럽위원회로부터 승인을 받았습니다. 이 항체-약물 복합체는 호지킨림프종의 결정적 표지인 CD30을 표적으로 하며, 임상시험 결과 ADCETRIS와 AVD 병용요법은 표준치료 대비 무진행생존기간과 전체생존기간을 모두 유의미하게 개선하는 것으로 나타났습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 한국 시장
제17장 서유럽 시장
제18장 영국 시장
제19장 독일 시장
제20장 프랑스 시장
제21장 동유럽 시장
제22장 북미 시장
제23장 미국 시장
제24장 캐나다 시장
제25장 남미 시장
제26장 중동 시장
제27장 아프리카 시장
제28장 시장 규제 상황과 투자환경
제29장 경쟁 구도와 기업 개요
제30장 세계 시장 경쟁 벤치마킹과 대시보드
제31장 주요 인수합병(M&A)
제32장 시장 잠재력이 높은 국가, 부문, 전략
제33장 부록
LSH
영문 목차
영문목차
Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) that targets CD30, a protein expressed on the surface of certain cancer cells, including those associated with Hodgkin lymphoma and systemic anaplastic large cell lymphoma. It combines a monoclonal antibody with the cytotoxic agent monomethyl auristatin E (MMAE) to deliver targeted chemotherapy directly to cancer cells, enhancing treatment effectiveness while minimizing off-target side effects.
The main forms of Adcetris include powder and liquid. Adcetris is provided as a sterile, white to off-white lyophilized powder in single-dose vials, which healthcare professionals reconstitute with a specified volume of sterile water prior to intravenous infusion. The various indications include Hodgkin lymphoma, systemic anaplastic large-cell lymphoma, cutaneous T-cell lymphoma, and others, and it is used across settings such as hospitals, drug stores, and other healthcare facilities.
Tariffs have impacted the adcetris market by increasing costs associated with imported biologic raw materials, specialized manufacturing inputs, and cold-chain logistics services. These added costs have influenced pricing strategies and reimbursement discussions, particularly in emerging oncology markets dependent on imports. Hospital and specialty pharmacy segments in regions such as asia pacific and latin america have experienced greater sensitivity due to higher import reliance. At the same time, tariffs have encouraged manufacturers to invest in localized biologics manufacturing and regional supply hubs. This shift supports long-term supply stability and reduces future exposure to cross-border trade disruptions.
The adcetris market research report is one of a series of new reports from The Business Research Company that provides adcetris market statistics, including adcetris industry global market size, regional shares, competitors with a adcetris market share, detailed adcetris market segments, market trends and opportunities, and any further data you may need to thrive in the adcetris industry. This adcetris market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The adcetris market size has grown strongly in recent years. It will grow from $1.4 million in 2025 to $1.52 million in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to advances in monoclonal antibody research, rising incidence of hodgkin lymphoma, unmet needs in relapsed cancers, clinical success of targeted therapies, regulatory approvals for adc drugs.
The adcetris market size is expected to see strong growth in the next few years. It will grow to $2.12 million in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to expansion into additional indications, increasing oncology biologics investment, growth in personalized medicine adoption, rising healthcare expenditure on cancer, improved adc manufacturing scalability. Major trends in the forecast period include expanded use of antibody drug conjugates in oncology, growing preference for targeted cancer therapies, rising combination therapy adoption, increased focus on rare lymphoma treatments, improved clinical outcomes in cd30-positive cancers.
The increasing prevalence of cancer is expected to drive the growth of the Adcetris market in the coming years. Cancer encompasses a group of diseases marked by the uncontrolled growth and spread of abnormal cells within the body. The rising incidence of cancer is attributed to factors such as unhealthy lifestyle choices, including poor diet and physical inactivity, greater exposure to environmental pollutants, and improvements in diagnostic techniques that enable earlier and more frequent detection. Adcetris provides notable benefits for cancer patients by selectively targeting CD30-positive cancer cells and delivering a potent cytotoxic agent directly to the tumor, which enhances treatment effectiveness while reducing systemic side effects. This targeted approach offers an important therapeutic option for patients with certain forms of Hodgkin lymphoma and other malignancies that express CD30. For example, in January 2023, according to the American Cancer Society, a US-based non-profit cancer advocacy organization, approximately 1,958,310 new cancer cases were reported in the United States in 2023, along with 609,820 cancer-related deaths. Therefore, the growing burden of cancer is contributing to the expansion of the Adcetris market.
A key trend shaping the Adcetris market is the emphasis on developing improved antibody-drug conjugates (ADCs) and enhanced drug-delivery approaches, including combination therapies, to increase therapeutic efficacy, limit adverse effects, and more precisely target cancer cells. Combination therapies involve the use of two or more agents with different mechanisms of action, often working synergistically to improve treatment outcomes, reduce drug resistance, and potentially lower toxicity compared with single-agent therapy. For instance, in October 2023, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, received approval from the European Commission for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for the treatment of adults with previously untreated CD30-positive Stage III Hodgkin lymphoma. This antibody-drug conjugate targets CD30, a defining marker of Hodgkin lymphoma, and clinical trial results showed that the ADCETRIS-plus-AVD regimen significantly improved both modified progression-free survival and overall survival compared with standard therapies.
In January 2024, Pfizer Inc., a US-based pharmaceutical company, completed the acquisition of Seagen Inc. for $43 billion. Through this acquisition, Pfizer aims to strengthen its oncology portfolio by incorporating Seagen's innovative antibody-drug conjugates, including Adcetris, thereby expanding its targeted cancer therapy offerings, supporting growth in oncology, and accelerating the delivery of advanced cancer treatments to patients worldwide. Seagen Inc. is a US-based biotechnology company that develops and commercializes Adcetris.
Major companies operating in the adcetris market are Takeda Pharmaceutical Company Limited, Seagen Inc.
North America was the largest region in the adcetris market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adcetris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the adcetris market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
The adcetris market consists of sales of brentuximab vedotin-based therapies such as antibody-drug conjugates (ADCs), bispecific antibodies, and immune checkpoint inhibitors for the treatment of lymphoma and related cancers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Adcetris Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses adcetris market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for adcetris ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The adcetris market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Type: Powder; Liquid
2) By Indication: Hodgkin Lymphoma; Systemic Anaplastic Large Cell Lymphoma; Cutaneous T-Cell Lymphoma; Other Indication
3) By Application: Hospital; Drugs Store; Other Applications
Companies Mentioned: Takeda Pharmaceutical Company Limited; Seagen Inc.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
4.1.4 Industry 4.0 & Intelligent Manufacturing
4.1.5 Internet Of Things (IoT), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
4.2.1 Expanded Use Of Antibody Drug Conjugates In Oncology
4.2.2 Growing Preference For Targeted Cancer Therapies
4.2.3 Rising Combination Therapy Adoption
4.2.4 Increased Focus On Rare Lymphoma Treatments
4.2.5 Improved Clinical Outcomes In CD30-Positive Cancers
5. Adcetris Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Oncology Specialty Clinics
5.3 Cancer Treatment Centers
5.4 Specialty Pharmacies
5.5 Research Institutions
6. Adcetris Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Adcetris Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Adcetris PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Adcetris Market Size, Comparisons And Growth Rate Analysis
7.3. Global Adcetris Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Adcetris Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Adcetris Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Adcetris Market Segmentation
9.1. Global Adcetris Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Powder, Liquid
9.2. Global Adcetris Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma, Cutaneous T-Cell Lymphoma, Other Indication
9.3. Global Adcetris Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospital, Drugs Store, Other Applications
10. Adcetris Market Regional And Country Analysis
10.1. Global Adcetris Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Adcetris Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
11. Asia-Pacific Adcetris Market
11.1. Asia-Pacific Adcetris Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Adcetris Market, Segmentation By Type, Segmentation By Indication, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Adcetris Market
12.1. China Adcetris Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Adcetris Market, Segmentation By Type, Segmentation By Indication, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Adcetris Market
13.1. India Adcetris Market, Segmentation By Type, Segmentation By Indication, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Adcetris Market
14.1. Japan Adcetris Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Adcetris Market, Segmentation By Type, Segmentation By Indication, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Adcetris Market
15.1. Australia Adcetris Market, Segmentation By Type, Segmentation By Indication, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. South Korea Adcetris Market
16.1. South Korea Adcetris Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
16.2. South Korea Adcetris Market, Segmentation By Type, Segmentation By Indication, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. Western Europe Adcetris Market
17.1. Western Europe Adcetris Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. Western Europe Adcetris Market, Segmentation By Type, Segmentation By Indication, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. UK Adcetris Market
18.1. UK Adcetris Market, Segmentation By Type, Segmentation By Indication, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. Germany Adcetris Market
19.1. Germany Adcetris Market, Segmentation By Type, Segmentation By Indication, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. France Adcetris Market
20.1. France Adcetris Market, Segmentation By Type, Segmentation By Indication, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. Eastern Europe Adcetris Market
21.1. Eastern Europe Adcetris Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
21.2. Eastern Europe Adcetris Market, Segmentation By Type, Segmentation By Indication, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. North America Adcetris Market
22.1. North America Adcetris Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
22.2. North America Adcetris Market, Segmentation By Type, Segmentation By Indication, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. USA Adcetris Market
23.1. USA Adcetris Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
23.2. USA Adcetris Market, Segmentation By Type, Segmentation By Indication, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Canada Adcetris Market
24.1. Canada Adcetris Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
24.2. Canada Adcetris Market, Segmentation By Type, Segmentation By Indication, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. South America Adcetris Market
25.1. South America Adcetris Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
25.2. South America Adcetris Market, Segmentation By Type, Segmentation By Indication, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Middle East Adcetris Market
26.1. Middle East Adcetris Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Middle East Adcetris Market, Segmentation By Type, Segmentation By Indication, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Africa Adcetris Market
27.1. Africa Adcetris Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
27.2. Africa Adcetris Market, Segmentation By Type, Segmentation By Indication, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. Adcetris Market Regulatory and Investment Landscape
29. Adcetris Market Competitive Landscape And Company Profiles
29.1. Adcetris Market Competitive Landscape And Market Share 2024
29.1.1. Top 10 Companies (Ranked by revenue/share)
29.2. Adcetris Market - Company Scoring Matrix
29.2.1. Market Revenues
29.2.2. Product Innovation Score
29.2.3. Brand Recognition
29.3. Adcetris Market Company Profiles
29.3.1. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
29.3.2. Seagen Inc. Overview, Products and Services, Strategy and Financial Analysis
30. Global Adcetris Market Competitive Benchmarking And Dashboard
31. Key Mergers And Acquisitions In The Adcetris Market
32. Adcetris Market High Potential Countries, Segments and Strategies
32.1 Adcetris Market In 2030 - Countries Offering Most New Opportunities
32.2 Adcetris Market In 2030 - Segments Offering Most New Opportunities
